This trial is testing a new drug to see if it's safe and effective at reducing levels of Lipoprotein(a) in the blood.
23 Primary · 5 Secondary · Reporting Duration: up to 365 days
79 Total Participants · 2 Treatment Groups
Primary Treatment: AMG 890 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: